Saar Gill

Learn More
Monoclonal antibodies are standard therapeutics for several cancers including the anti-CD20 antibody rituximab for B cell non-Hodgkin lymphoma (NHL). Rituximab and other antibodies are not curative and must be combined with cytotoxic chemotherapy for clinical benefit. Here we report the eradication of human NHL solely with a monoclonal antibody therapy(More)
Introduction Anti-CD19 chimeric antigen receptor T cells (CART19) and bi-specific anti-CD19/CD3 antibodies (blinatumo-mab) are generating unprecedented complete responses in relapsing/refractory B-cell acute lymphoblastic leuke-mia (r/r BALL). However, a subset of patients still relapse and about 30-50% of these relapses are characterized by the loss of(More)
  • 1